Comment: Sulfonamide cross-reactivity: Fact or fiction? [10] (multiple letters)

Annals of Pharmacotherapy

Volumn 39, Issue 7-8, 2005, Pages 1372-1373

  Phillips, Elizabeth J ^a   Knowles, Sandra R ^b   Johnson, Kelly K ^c   Green, David L ^d   Rife, Jason P ^e   Limon, Lynn ^f  

^a ST PAUL S HOSPITAL   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^d Sherman Hospital   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIINFECTIVE AGENT; AROMATIC AMINE; COTRIMOXAZOLE; CYTOCHROME P450; DARUNAVIR; HYDROXYLAMINE; NITROSAMINE; SULFAMETHOXAZOLE; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; SULFONYLARYLAMINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG CROSS REACTIVITY; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; SKIN MANIFESTATION;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; SULFONAMIDES;

EID: 21744449489     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E350a     Document Type: Letter

References (0)